• RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs1
• Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis1,2
• A new oral solution of RINVOQ was approved for use in patients with pJIA1
• RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases1

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.